Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

By WebmasterNovember 17, 2022November 1st, 2024No Comments

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

See more here

Previous PostDr. Sean Lyden Agrees to Assume the Role of Chief Medical Consultant and Join the VESTECK Scientific Advisory Board
Next PostImmunome Reports Third Quarter 2022 Financial Results

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostDr. Sean Lyden Agrees to Assume the Role of Chief Medical Consultant and Join the VESTECK Scientific Advisory Board

Next PostImmunome Reports Third Quarter 2022 Financial Results